ReNerve

ReNerve ROCE

The Return on Capital Employed (ROCE) of ReNerve (RNV.AX) as of Nov 5, 2026 is -205.16 %. In the previous year, Return on Capital Employed (ROCE) was -85.73 % — a change of 139.31% (lower).

ROCE

-205.16 %

YoY

139.31%

Last updated:

In 2026, ReNerve's return on capital employed (ROCE) was -205.16 %, a 139.31% increase from the -85.73 % ROCE in the previous year.

The ReNerve ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2024
-42.00 AUD
Jan 1, 2025
-85.73 AUD
Jan 1, 2026
-205.16 AUD
The ReNerve ROCE history
YEARROCEYoY
-205.16 %+139.31%
-85.73 %+104.11%
-42.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd develops medical devices for nerve repair and soft tissue surgery, focusing on products that accelerate regeneration and prevent scarring. The company offers NervAlign Nerve Cuff, a protective wrap for repaired nerves, and NervAlign Nerve Graft, which allows surgeons to repair damaged nerves without harvesting the sural nerve. NervAlign Bionic Nerve combines polymer technology with nerve grafts to create a replacement nerve using shaped ionic polymers for distal nerve stimulation. These products target surgical procedures requiring nerve repair, with hospitals and surgical centers as primary buyers. The company's revenue comes from selling NervAlign products directly to healthcare providers involved in nerve repair surgeries. NervAlign Nerve Cuff is designed for protecting repaired nerves during surgery, while NervAlign Nerve Graft eliminates the need for patient nerve harvesting. NervAlign Bionic Nerve represents a future product line aiming to provide advanced nerve replacement solutions. The target market includes surgical teams specializing in peripheral nerve procedures and medical facilities equipped for complex soft tissue surgeries. ReNerve Ltd's products are positioned for use in peripheral nerve repair and related soft tissue surgical procedures. The NervAlign Nerve Cuff protects injured nerves during surgical repair, the NervAlign Nerve Graft enables nerve repair without patient nerve harvesting, and NervAlign Bionic Nerve aims to stimulate distal nerve ends using ionic polymers. These products are sold to hospitals and surgical centers that perform nerve repair surgeries, with the company focusing on accelerating tissue regeneration and reducing complications. ReNerve is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ReNerve's Return on Capital Employed (ROCE)

ReNerve's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ReNerve's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ReNerve's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ReNerve’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ReNerve stock

Return on Capital Employed (ROCE) of ReNerve is -205.16 % in 2026.

Return on Capital Employed (ROCE) of ReNerve changed from -85.73 % to -205.16 %, representing a 139.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) ReNerve since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s ReNerve with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — ReNerve

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — ReNerve